BACKGROUND: Ischemic cerebrovascular accidents remain a leading cause of morbidity and mortality. Thrombolytic therapy for acute ischemic stroke within 3h of symptom onset of highly select patients has been advocated by some groups since 1995, but trials have yielded inconsistent outcomes. One recent trial demonstrated significant improvement when the therapeutic window was extended to 4.5h. CLINICAL QUESTION: Does the intravenous systemic administration of tPA within 4.5h to select patients with acute ischemic stroke improve functional outcomes? EVIDENCE REVIEW: All randomized controlled trials enrolling patients within 4.5h were identified, in addition to a meta-analysis of these trial data. RESULTS: The National Institute of Neurological Disorders and Stroke (NINDS) and European Cooperative Acute Stroke Study III (ECASS III) clinical trials demonstrated significantly improved outcomes at 3 months, with increased rates of intracranial hemorrhage, whereas ECASS II and the Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study showed increased hemorrhagic complications without improving outcomes. Meta-analysis of trial data from all ECASS trials, NINDS, and ATLANTIS suggest that thrombolysis within 4.5h improves functional outcomes. CONCLUSION: Ischemic stroke tPA treatment within 4.5h seems to improve functional outcomes and increases symptomatic intracranial hemorrhage rates without significantly increasing mortality. Copyright Â
BACKGROUND:Ischemic cerebrovascular accidents remain a leading cause of morbidity and mortality. Thrombolytic therapy for acute ischemic stroke within 3h of symptom onset of highly select patients has been advocated by some groups since 1995, but trials have yielded inconsistent outcomes. One recent trial demonstrated significant improvement when the therapeutic window was extended to 4.5h. CLINICAL QUESTION: Does the intravenous systemic administration of tPA within 4.5h to select patients with acute ischemic stroke improve functional outcomes? EVIDENCE REVIEW: All randomized controlled trials enrolling patients within 4.5h were identified, in addition to a meta-analysis of these trial data. RESULTS: The National Institute of Neurological Disorders and Stroke (NINDS) and European Cooperative Acute Stroke Study III (ECASS III) clinical trials demonstrated significantly improved outcomes at 3 months, with increased rates of intracranial hemorrhage, whereas ECASS II and the Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study showed increased hemorrhagic complications without improving outcomes. Meta-analysis of trial data from all ECASS trials, NINDS, and ATLANTIS suggest that thrombolysis within 4.5h improves functional outcomes. CONCLUSION:Ischemic stroketPA treatment within 4.5h seems to improve functional outcomes and increases symptomatic intracranial hemorrhage rates without significantly increasing mortality. Copyright Â
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Stephen M Davis; Geoffrey A Donnan; Mark W Parsons; Christopher Levi; Kenneth S Butcher; Andre Peeters; P Alan Barber; Christopher Bladin; Deidre A De Silva; Graham Byrnes; Jonathan B Chalk; John N Fink; Thomas E Kimber; David Schultz; Peter J Hand; Judith Frayne; Graeme Hankey; Keith Muir; Richard Gerraty; Brian M Tress; Patricia M Desmond Journal: Lancet Neurol Date: 2008-02-28 Impact factor: 44.182
Authors: Pooja Khatri; Michael D Hill; Yuko Y Palesch; Judith Spilker; Edward C Jauch; Janice A Carrozzella; Andrew M Demchuk; Renee' Martin; Patrick Mauldin; Catherine Dillon; Karla J Ryckborst; Scott Janis; Thomas A Tomsick; Joseph P Broderick Journal: Int J Stroke Date: 2008-05 Impact factor: 5.266
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Werner Hacke; Mónica Millán; Keith Muir; Risto O Roine; Danilo Toni; Kennedy R Lees Journal: Lancet Date: 2008-09-12 Impact factor: 79.321
Authors: Yaoming Wang; Zhenggang Zhang; Nienwen Chow; Thomas P Davis; John H Griffin; Michael Chopp; Berislav V Zlokovic Journal: Stroke Date: 2012-07-17 Impact factor: 7.914
Authors: Maria Carolina O Rodrigues; Dmitriy Dmitriev; Antonio Rodrigues; Loren E Glover; Paul R Sanberg; Julie G Allickson; Nicole Kuzmin-Nichols; Naoki Tajiri; Kazutaka Shinozuka; Svitlana Garbuzova-Davis; Yuji Kaneko; Cesar V Borlongan Journal: Interv Med Appl Sci Date: 2012-06
Authors: Yaoming Wang; Zhen Zhao; Nienwen Chow; Padmesh S Rajput; John H Griffin; Patrick D Lyden; Berislav V Zlokovic Journal: Stroke Date: 2013-10-24 Impact factor: 7.914
Authors: Huang Guo; Theresa M Barrett; Zhihui Zhong; José A Fernández; John H Griffin; Robert S Freeman; Berislav V Zlokovic Journal: Mol Neurodegener Date: 2011-02-03 Impact factor: 14.195